TrialRMD open2025

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study.

Nan Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.